Bristol-Myers Squibb (BMS) announced that it will be acquiring Celgene for $74 billion; Congress has confirmed the Trump administration's nominees for science advisor and drug czar; and drugmakers kicked off 2019 with drug price hikes.
In a press release today, Bristol-Myers Squibb (BMS) announced that it will be acquiring Celgene. According to BMS, the $74 billion acquisition will allow the 2 companies to address the needs of patients with cancer, inflammatory and immunologic disease, and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. The combined company will have 9 products with more than $1 billion in annual sales. The transaction is expected to close in the third quarter of 2019.
On Wednesday, Congress confirmed the Trump administration’s nominees for science advisor and drug czar following 2 years of vacancy, reported STAT News. Appointed science advisor Kelvin Droegmeier is a meteorologist and former professor at the University of Oklahoma. The Senate also confirmed James Carroll to head the Office of National Drug Control Policy, providing the White House with a top drug advisor amid the national opioid epidemic.
While drugmakers entered the year with price increases on more than 250 prescription drugs, the pace of price hikes was slower than last year, according to Reuters. The overall number of price increases was down by around one-third from 2018, when drugmakers raised the prices on more than 400 drugs. AbbVie’s Humira and 50 Allergan drugs were among those that saw price increases. Amid the price hikes, President Trump during a meeting with his Cabinet on Wednesday said he expected to see a tremendous decrease in drug prices.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More